GlassScriptPhysician profile
Dinas Aleksonis
NPI 1255505608
$4,419.26
in general payments reported to CMS, 2019-2025
26 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 79% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $210 · 2021: $349 · 2022: $302 · 2023: $770 · 2024: $783 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,305.56 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $365.09 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Genentech USA, INC. | $291.69 | 2019-2020 | |
| Pulmonx Corporation | $284.36 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Genzyme Corporation | $276.38 | 2022-2025 | |
| Insmed, INC. | $262.82 | 2023-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $221.67 | 2021-2025 | Smartvest |
| Edwards Lifesciences Corporation | $168.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.00 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $140.26 | 2022-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $122.43 | 2019-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $106.80 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $99.35 | 2023-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $89.88 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $76.55 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.69 | 2019-2023 | Zerbaxa, Dificid |
| Philips North America LLC | $68.38 | 2019-2025 | Vest Therapy Und |
| Avadel Cns Pharmaceuticals, LLC | $60.81 | 2024-2025 | Lumryz |
| Ceribell, INC. | $60.48 | 2025 | Pocket Eeg Device |
| Amgen INC. | $42.82 | 2022 | |
| Mylan Specialty L.P. | $35.62 | 2022-2024 | Yupelri |
| Baxter Healthcare | $32.98 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $24.65 | 2023 | Inspire |
| Inogen, INC. | $18.32 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Vapotherm INC | $17.01 | 2021 | |
| La Jolla Pharmaceutical Company | $15.40 | 2024 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinas Aleksonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.